Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) and Urogen Pharma (NASDAQ:URGN – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.
Risk and Volatility
Lifecore Biomedical has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.
Insider & Institutional Ownership
83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by insiders. Comparatively, 4.8% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lifecore Biomedical | 1 | 1 | 1 | 0 | 2.00 |
| Urogen Pharma | 1 | 1 | 8 | 0 | 2.70 |
Lifecore Biomedical currently has a consensus price target of $6.50, indicating a potential upside of 57.77%. Urogen Pharma has a consensus price target of $52.38, indicating a potential upside of 23.79%. Given Lifecore Biomedical’s higher possible upside, equities analysts plainly believe Lifecore Biomedical is more favorable than Urogen Pharma.
Profitability
This table compares Lifecore Biomedical and Urogen Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lifecore Biomedical | -29.93% | N/A | -16.16% |
| Urogen Pharma | -51.73% | N/A | -43.79% |
Earnings & Valuation
This table compares Lifecore Biomedical and Urogen Pharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lifecore Biomedical | $128.87 million | 1.21 | -$40.50 million | ($1.07) | -3.85 |
| Urogen Pharma | $109.79 million | 18.84 | -$153.49 million | ($1.98) | -21.37 |
Lifecore Biomedical has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.
Summary
Lifecore Biomedical beats Urogen Pharma on 8 of the 13 factors compared between the two stocks.
About Lifecore Biomedical
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
About Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
